The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it.
Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe.
Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.
Maximising the strength of patent protection should be an important objective of any R&D pharma company. Christine Goddard and Janis Fraser of law firm Fish & Richardson offer their six top tips for success.
Google’s new contact lens sensor is just one of the latest eye-based devices that has vast potential in the field of medicine. LSIPR reports.
The US Supreme Court has now heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. This could fundamentally change how patent decisions are reviewed by the Federal Circuit and the deference given to district court rulings, says Felicia Boyd of Barnes & Thornburg.
The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports.
Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi.
Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.
Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry.